ALT
Altimmune Inc.
$4.81
+$0.34(+7.61%)
63
Overall
60
Value
66
Tech
--
Quality
Market Cap
$484.78M
Volume
3.48M
52W Range
$2.90 - $10.88
Target Price
$17.88
Company Overview
| Mkt Cap | $484.78M | Price | $4.81 |
| Volume | 3.48M | Change | +7.61% |
| P/E Ratio | -5.1 | Open | $4.46 |
| Revenue | $20.0K | Prev Close | $4.47 |
| Net Income | $-95.1M | 52W Range | $2.90 - $10.88 |
| Div Yield | N/A | Target | $17.88 |
| Overall | 63 | Value | 60 |
| Quality | -- | Technical | 66 |
No chart data available
About Altimmune Inc.
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Sector: Healthcare
Industry: Biotechnology
Latest News
MicroSalt plc Expands Share Issuance Following Stock Option Exercise
TipRanks UK Auto-Generated Newsdesk•2 days ago
Altamira Gold Discovers High-Grade Gold at Morro Verde Target
TipRanks Canadian Auto-Generated Newsdesk•5 days ago
Galectin Therapeutics Reports Q3 2025 Financials
TipRanks Auto-Generated Newsdesk•9 days ago
MicroSalt Projects Robust Growth with Strategic Partnerships and New Orders
TipRanks UK Auto-Generated Newsdesk•10 days ago
Alvarium Tiedemann Holdings Delays 10-Q Filing
TipRanks Auto-Generated Newsdesk•11 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ALT | $4.81 | +7.6% | 3.48M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |